Baxter Recalls One Lot of Cefazolin in Dextrose Injection After Cardboard Particles Found

What the recall covers

Baxter issued a voluntary nationwide recall on July 24, 2026, for one lot of cefazolin in dextrose injection, USP, 2 g/100 mL, equivalent to 20 mg/mL. According to the FDA notice, the action followed a complaint involving cardboard particulate matter found in the solution.

This is a lot-specific product-quality action, not a recall of cefazolin generally. It does not indicate a class-wide safety concern with the antibiotic, and unaffected cefazolin products remain distinct from the recalled inventory. Facilities should use the FDA notice and Baxter’s communication to match the complete lot, product and expiration identifiers before determining whether a bag is affected.

The distinction matters because cefazolin is widely used in perioperative care. A narrowly targeted recall can still disrupt operating rooms if stock has already been distributed across central pharmacies, surgical satellites, automated dispensing cabinets, anesthesia work areas and procedure units. Conversely, removing all cefazolin without checking identifiers could unnecessarily constrain supply and complicate antimicrobial stewardship.

The FDA announcement is a regulatory recall notice rather than a clinical study. It reports the defect and the manufacturer’s response, but it does not provide a treated-population denominator, a comparator group, an incidence estimate or a follow-up period from which patient risk can be quantified.

Why intravenous particles are clinically important

Visible foreign matter is unacceptable in an injectable product because intravenous administration bypasses several of the body’s usual physical barriers. The clinical consequences depend on factors that include particle composition, size, number, route of administration, infusion site and the patient’s underlying condition.

The FDA recall notice describes potential outcomes from intravenous particulate exposure that range from local irritation, swelling, allergic reactions and phlebitis to more serious vascular or organ effects. Particles entering the circulation can obstruct small vessels or lodge in tissues, creating risks such as granuloma formation, tissue ischemia, pulmonary embolic phenomena, pulmonary dysfunction, stroke or death. Listing these possible outcomes does not establish that they occurred in recipients of this lot or quantify their likelihood.

The finding of cardboard material also should not be interpreted beyond the available evidence. Particulate contamination is the stated basis for the recall; the notice does not by itself demonstrate loss of cefazolin potency, failure of antimicrobial activity or microbial contamination. Those are separate quality questions requiring supporting test results.

FDA guidance on injectable-product inspection emphasizes that visible-particle control involves manufacturing controls, inspection systems, defect investigation and appropriate quality decisions. Bedside visual inspection remains useful, but it cannot establish that a product is free of particles: some particles may be difficult to see because of their size, color, movement, container characteristics or lighting conditions.

For the same reason, an apparently clear bag from the recalled lot should not be released for use. Nor should an in-line filter be treated as a way to salvage recalled inventory. Filtration performance varies by particle characteristics and device specifications, and the recall does not authorize administration after filtering.

The operational response for pharmacies and perioperative teams

The first task is containment. Pharmacy leadership should compare inventory against the exact identifiers in the FDA and manufacturer notices, then quarantine matching units so they cannot be selected, dispensed or transferred. The search should extend beyond the main pharmacy to operating-room cores, procedural areas, anesthesia supplies, automated dispensing cabinets and any off-site locations supplied by the same system.

Electronic and logistical controls can reduce accidental use. Depending on local capabilities, these may include blocking the affected lot in inventory systems, placing dispensing alerts, documenting the quantity quarantined and reconciling units already distributed. Quarantined product should be handled according to Baxter’s return instructions rather than discarded in a way that prevents reconciliation.

Perioperative services need prompt notification because cefazolin is often prepared or staged before a procedure. Pharmacy, anesthesia, surgery, nursing, infection prevention, antimicrobial stewardship, supply-chain staff and medication-safety teams should share one verified description of the affected product. Communications should make clear that the recall is lot-specific and should identify where unaffected stock can be obtained.

Continuity planning is equally important. Facilities can review scheduled case volume, available unaffected cefazolin inventory and expected replenishment, while protecting urgent procedures from avoidable delays. Any alternative prophylactic agent should be selected through established institutional protocols and patient-specific clinical assessment, not improvised solely because a recalled lot was removed.

If records indicate that a recalled unit may already have been administered, the response shifts from inventory control to exposure assessment. Lot-level dispensing and administration records, where available, can help establish who received the product and when. Clinicians can then evaluate reported symptoms and the circumstances of administration, while risk-management and pharmacovigilance teams determine appropriate documentation, communication and reporting.

Suspected adverse events or product-quality problems can be reported through the FDA’s MedWatch program, following the channels described in the recall notice. Reporting is especially useful when it includes the product name, lot identifier, administration route, timing, clinical findings and outcome, without delaying necessary clinical evaluation.

What the notice cannot tell us

The principal limitation is the evidence type. A recall notice documents a quality defect and precautionary market action; it is not designed to estimate causal risk. The public information does not provide particle counts, a particle-size distribution, the number of units potentially administered or comparative clinical outcomes.

Accordingly, the probability of harm after an individual exposure cannot be calculated from the notice. Serious outcomes are biologically plausible consequences of intravenous foreign particles, but plausibility is not evidence that a particular recipient was injured. Additional investigation may clarify the defect’s origin, distribution and clinical significance.

Operationally, the immediate evidence supports removing the specified lot, tracing its distribution and preserving access to unaffected perioperative antibiotics. It does not support a class-wide withdrawal of cefazolin or assumptions about harm in every patient who may have received an affected unit.

Questions clinicians ask

Should all cefazolin inventory be removed?

No. The FDA action applies to one specified lot of cefazolin in dextrose injection, not to cefazolin as a drug class. Pharmacies should match the full identifiers in the recall notice, quarantine affected units and keep clearly unaffected inventory available through controlled workflows.

Can a recalled bag be used if no particle is visible?

No recalled unit should be released merely because it appears clear on visual inspection. Inspection cannot reliably detect every particle, and the voluntary recall removes the specified lot from use. Filtering the solution is not an authorized workaround for returning recalled inventory to clinical service.

What should happen if the product may already have been administered?

Facilities should use available lot-level records to confirm the exposure and support clinical review. The FDA notice does not establish a universal testing or screening protocol; assessment should reflect the administration circumstances and any symptoms, with suspected adverse events or quality problems reported through appropriate institutional and FDA channels.

Does the recall require a different perioperative antibiotic policy?

The notice supports removing the affected lot, not abandoning cefazolin generally. Teams should preserve prophylaxis using unaffected supply when available and follow established institutional guidance if an alternative is needed, accounting for the procedure, allergy history, likely pathogens, patient factors and local stewardship policy.

References

1. Baxter Issues Voluntary Nationwide Recall of Cefazolin in Dextrose Injection, USP, 2 g/100 mL (20 mg/mL) — U.S. Food and Drug Administration, 2026 2. Inspection of Injectable Products for Visible Particulates — U.S. Food and Drug Administration, 2021 3. Drug Recalls — U.S. Food and Drug Administration, n.d.